Key Takeaways
- Health Canada approved Apobiologix’s Hadlima biosimilar for adalimumab (Humira) in additional indications.
- Biosimilar adalimumab now holds 44% of new Canadian adalimumab prescriptions up from 8% in 2023.
- AbbVie (Humira’s originator) has seen Canadian revenue from the drug decline 28% year-over-year.
- Canada’s pan-Canadian Pharmaceutical Alliance has mandated biosimilar transitions in seven provinces.
Health Canada’s approval of expanded indications for Apobiologix’s Hadlima a biosimilar to AbbVie’s blockbuster Humira (adalimumab) is the latest chapter in Canada’s accelerating biosimilar adoption story. What began as a fringe policy debate five years ago has become mainstream: seven provinces now have policies requiring eligible patients to switch from originators to biosimilars when clinically appropriate, dramatically reshaping the economics of Canada’s biologic drug market.
The Biosimilar Market Shift
| Metric | 2023 | 2026 | Change |
|---|---|---|---|
| Biosimilar adalimumab market share | 8% | 44% | +36pp |
| Avg. adalimumab price (CAD/year) | $24,800 | $18,200 | -27% |
| Number of approved adalimumab biosimilars | 3 | 7 | +4 |
| Provinces with biosimilar transition policy | 3 | 7 | +4 |
What This Means for Investors
For investors in originator biologic companies AbbVie, Janssen, Roche the Canadian biosimilar environment is a preview of global market dynamics that will play out over the next decade. For investors in biosimilar manufacturers Samsung Bioepis, Celltrion, Apobiologix (private) Canada’s aggressive transition policies represent growing market opportunity. And for healthcare system payers, the savings are beginning to materialize: CADTH estimates $1.8B in cumulative savings from biosimilar transitions through 2025.